Navigation Links
Enbrel Will Remain Decision Resources' Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
Date:1/12/2010

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer/Takeda's Enbrel will retain Decision Resources' proprietary clinical gold standard status for the treatment of rheumatoid arthritis through 2018. Although Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi offers delivery advantages over Enbrel in formulation (potentially offered in both subcutaneous and intravenous formulations) and dosing frequency (once monthly compared with once or twice weekly for Enbrel), neither Simponi nor any other rheumatoid arthritis biologic have the same effect as Enbrel in inhibiting/slowing structural damage progression.

The new report entitled Rheumatoid Arthritis: Opportunity Awaits Therapies that Meet Physicians' Efficacy Expectations in TNF-α Inhibitor-Refractory Patients also finds that rheumatologists are unwilling to compromise on efficacy or convenient delivery for a disease-modifying drug with a novel mechanism of action for patients who are refractory to tumor necrosis factor alpha (TNF-alpha) inhibitors, even if such an agent entered the market at a lower price point than leading biologics. Surveyed U.S. rheumatologists stated that such a drug (that doesn't compromise on efficacy) could be prescribed to 63 percent of eligible U.S. patients. Surveyed European rheumatologists indicated that such an agent could be prescribed to 75 percent of eligible European patients.

"Because we believe the TNF-alpha inhibitors will remain the most prescribed treatments for patients who have failed or lost response to conventional disease-modifying antirheumatic drugs, we profiled the opportunity for an agent in the TNF-alpha inhibitor-refractory population in our study. High price, intravenous delivery route and the potential for harmful side-effects are all drawbacks to current biologic agents used to treat TNF-alpha inhibitor-refractory patients. However, given a drug with incremental safety, delivery and even cost advantages, physicians are still unwilling to compromise on efficacy," stated Decision Resources Analyst Kyle Crowell.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market? Exploring Drug Attributes Needed to Maximize Patient Share. This webinar will be held on Wednesday, January 27, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About the Report

Rheumatoid Arthritis: Opportunity Awaits Therapies that Meet Physicians' Efficacy Expectations in TNF-α Inhibitor-Refractory Patients is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

SOURCE Decision Resources

RELATED LINKS
http://www.decisionresources.com

'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
2. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
3. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
4. Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018
5. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
6. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
7. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
8. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
9. Cardiac Disease in Women Remains Untreated for Decades
10. Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology
11. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
Breaking Medicine News(10 mins):